Supplementary information

FIgure S1



Figure S1. Validation of ATM and/or ATR inhibitors in HeLa_CFLAP_BRCA2_hTert cells. HeLa_CFLAP_BRCA2_hTert cells were treated with increasing concentrations of KU55933 (1μM, 20μM) or CGK733 (1μM, 20μM) for 1 h prior to addition of 2.5 mM hydroxyurea (HU) for 2 h (A) or irradiation (10 Gy) (B). The PI3 kinase inhibitor wortmannin was included for control. **(A)** Cell lysates obtained from HeLa_CFLAP_BRCA2_hTert cells with (+) or without (-) HU (2.5mM) treatment (2 h) were analyzed by Western blot with specific antibodies for Serine-317 phosphorylation of Chk1 (αph-Chk1 (Ser317)) or Threonine-68 phosphorylation of Chk2 (αph-Chk2 (Thr68)). Blots were reprobed with anti-Chk1, anti-Chk2 or anti-Actin antibodies for loading controls. **(B)** WB analysis of HeLa_CFLAP_BRCA2_hTert cells before or after irradiation. Phospho-Chk1 or phosphor-Chk2 was assessed as in (A).